Global Partners LP (GLP) Stock

Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims' innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.

Thousands of health-care executives descended on JPMorgan's annual health-care conference in San Francisco this week. The conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in New York City.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recently surprised investors when it cut its full-year revenue guidance ahead of an investor conference after sales of its GLP-1 drugs fell short of expectations.

For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinuation of GLP-1 agonists, medicines used to manage Type 2 diabetes and obesity. GLP-1 agonists, such as semaglutide marketed under brand names like Ozempic and Wegovy, are integral in treating metabolic disorders but often lead to side effects including sarcopenia and bone density loss.

Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.

CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market.